The vaccine against rinderpest is considered a milestone in the history of veterinary vaccine production (van Gelder and Makoschey [@CR72]). In 2011, Rinderpest, a deadly animal disease, was eradicated from the world. There is only one similar example for eradicated disease, that is smallpox in humans. The World Organization for Animal Health (OIE), is currently working on strategies to control other terrible infections including peste des petits ruminants (PPR), foot-and-mouth disease (FMD), and rabies. The global eradication of rinderpest has been a remarkable achievement for veterinary science. With the eradication of rinderpest in live animals livestock production in the world has become safer and livestock industries are less at risk (World Organization for Animal Health \[OIE\]).

Currently, there are no vaccines for several globally significant infections. The main problem is the complexity of correlates of protection. The other is difficulty in constructing the correct presentation of antigens for many of these lacking vaccines. Luckily, molecular technology has offered many new tools for developing vaccines (Plotkin [@CR50]). Modern vaccines are based on the scientific progress in virology, cell biology, and immunology (van Gelder and Makoschey [@CR72]). These molecular equipment and knowledges may enable the scientist to make more use of cellular and humoral immune responses to antigens that are the main features for achievement of vaccines now (Plotkin [@CR50]).

There are successful production of biotechnological-based vaccines used in protection against diseases, produced for use. These are virus-like particle, gene-deleted marker, subunit, DIVA, and DNA vaccines.

This chapter reviews the literature concerning the usefulness of livestock vaccination against and biotechnologies in vaccine development.

DNA Vaccines {#Sec1}
============

DNA vaccination presents a new simple concept in vaccination strategy. It is an antigen-encoding bacterial plasmid that produces an immune response when inoculated into a suitable host (Garmory et al. [@CR26]; Josefsberg and Barry [@CR36]). Potential applications of plasmid DNA and other gene therapy approaches have been a matter of debate for a long time (Wolff et al. [@CR80]). DNA vaccination elicits neutralizing antibodies and induces T helper cell response of Th1 phenotype and cytotoxic T-lymphocyte response (Donnelly et al. [@CR22]).

Immunization is carried out via ingestion of purified plasmid in the host cells and T cell recognition of antigen-presenting cells (APC) depends on their expression of a spectrum of peptides bound to class I and II major histocompatibility complex (MHC) molecules. Subsequent protein expression results in the presentation of normal or modified forms of the protein to the immune system (World Organization for Animal Health \[OIE\]).

DNA vaccines have more advantages than other vaccines. The first advantage is that DNA vaccines promote humoral immune response and cell-mediated immune response. These two responses are so critical that also known DNA vaccines can induce long-term immunity in many diseases. This has become a requirement for vaccine efficacy. DNA vaccines are easy to produce and purify, and this has enabled the production and evaluation of new DNA vaccines in animal models within months. Another advantage is the long shelf life of DNA vaccines and the capability to transport (no need to cold chain). Various studies, including on humans, show the reliability of DNA vaccines (Bagarazzi et al. [@CR5]; Kim et al. [@CR37]). DNA vaccinations have proved in rodents as efficient. Studies on DNA vaccination are continued even in outbred species (Carvalho et al. [@CR13]; Redding and Weiner [@CR53]). Currently, four DNA vaccines have been licensed for veterinary use. One is for swine in Australia, for growth of hormone releasing hormone, the other is against infectious hematopoietic necrosis virus for salmon in Canada, and the others are against west nile virus (WNV) for horses and melanoma for dogs in the USA (Kutzler and Weiner [@CR38]).

Optimization at various levels is required in large animal species to succeed for higher influence. These include vector modifications, DNA submission paths and procedure, addition of adjuvants, and antigen targeting to APC. Inadequate benefit of DNA vaccines in large animals is likely caused by ineffective transfection of the administered plasmids. The inefficiency of the vaccine interferes with sufficient induction of development of the immunity (Rao et al. [@CR52]).

Protective immunity has been accomplished with DNA vaccines with Pestivirus glycoprotein E2, which is the major protective antigen for bovine viral diarrhea virus (BVDV) in cattle, and classical swine fever virus (CSFV) in pigs. In poultry, the possiblity of DNA vaccination against flu using plasmids coding for hemagglutinin (HA), the main target for neutralizing antibodies, alone or in mixture with nucleoprotein (NP), the primary target of the cytotoxic lymphocyte (CTL) response, has been established by several studies (Brun et al. [@CR10]). Vaccines induce immunogenicity and enable protection with plasmid DNA against BHV in mice (Cox et al. [@CR15]), malaria in mice (Mor et al. [@CR45]; Sedegah et al. [@CR60]), hepatitis B in chimpanzees (Davis et al. [@CR16]), human immunodeficiency virus in rhesus monkeys (Lekutis et al. [@CR39]), influenza A virus in ferrets (Donnelly et al. [@CR21]), *Mycobacterium tuberculosis* in mice (Lowrie et al. [@CR41]; Lynch et al. [@CR42]), and genital herpes simplex virus in guinea pigs (Bourne et al. [@CR8]).

Apart from these trials, recently, DNA vaccines have entered phase I human clinical trials for protection against HIV, malaria, and influenza.

DNA vaccines against many diseases are evaluated in experimental studies and animal models.

Real-time PCR and histopathological examination confirmed that only low viral DNA loads and mild histopathological lesions appeared in pORF2-immunized mice following virus challenge to show protective immunity against porcine circovirus 2 by vaccination with ORF2-based DNA and subunit vaccines in mice (Shen et al. [@CR61]).

Bovine leukemia virus (BLV) envelope gene encoding extracellular and transmembrane glycoprotein gp51 and gp30 was cloned into vector under Human cytomegalovirus (CMV) intermediate early promoter for DNA vaccine construction. Cellular immune response was promoted when the intramuscular administration of this plasmid vector was done (Brillowska et al. [@CR9]). In another study, BLV transactivator Tax cloned into Mammalian cell expression plasmid pME18Neo showed that Th1 type immune response induced by Tax DNA vaccine inhibited BLV propagation in vaccinated sheep at the early phase of infection (Usui et al. [@CR69]).

Gogev et al. ([@CR27]) showed the efficacy of Bovine herpesvirus 1 DNA vaccine in cattle. In the study Bovine herpesvirus 1 glycoprotein C was used as antigen. In calves, the administration of recombinants Ad5CMVgD and/or Ad5CMVgC, or a composition of them, increase Bovine herpesvirus 1 neutralizing antibody responses and presented protection against challenge with BHV-1 Iowa strain (Gogev et al. [@CR27]).

Another research made on Bovine herpesvirus 1 DNA vaccine using Vector pBISIA88 expressed glycoprotein D (gD) (Pontarollo et al. [@CR51]) and Vector pMASIA expressed full-length BHV-1 gB (Huang et al. [@CR32]).

Schrijver et al. ([@CR58]) prepared a DNA vaccine by which the gE gene was changed by a gene encoding the G protein of Bovine Respiratory Syncytial Virus (BRSV) in a bovine herpesvirus 1 vector. As a result of the study the G protein of BRSV can stimulate considerable protection for BRSV infection in cattle, and the BHV1/BRSV-G vaccine protects powerfully against a subsequent BRSV and Bovine herpesvirus 1 infection (Schrijver et al. [@CR58]).

Vaccination and also poultry flock management are very important. Vaccine research and currently available commercial vaccine numbers are increasing day-by-day.

Sakaguchi et al. ([@CR57]) generated a plasmid vector expressing the Newcastle disease virus F protein (NDV-F) under the control of the human cytomegalovirus immediate early enhancer and chicken beta-actin gene promoter. Their results exhibit that the DNA vaccine is useful against the Newcastle disease (Sakaguchi et al. [@CR57]).

Park et al. ([@CR46]) generated a chimeric Avian Influenza Virus (AIV). This virus expressed the ectodomain of the hemagglutinin-neuraminidase gene in place of the neuraminidase protein of the H5N1 AIV. A single vaccination of chickens with this improved vaccine prototype virus induced strong immunity against H7N7, highly pathogenic AIV, and against Newcastle disease Virus (Park et al. [@CR46]). Park et al. ([@CR46]) proposed that chimeric constructs should be developed for convenient, inexpensive, and effective immunization against Newcastle disease and avian influenza in poultry (Park et al. [@CR46]).

DNA vaccines are evaluated not only for protection against viral or bacterial diseases but also against protozoan diseases that are associated with abortions in cattle.

Various experimental studies exist for protozoan diseases, one of which is recombinant DNA vaccine with NcSAG1 and NcSRS2 proteins against *Neospora caninum* for C57BL/6 mice (Cannas et al. [@CR11]).

Results suggested highly significant protective effect with combined DNA (based on NcSAG1)/recombinant antigen vaccine (based on NcSRS2) in cerebral neosporosis in mice (Cannas et al. [@CR11]).

Gene-Deleted Vaccines {#Sec2}
=====================

The availability of recombinant DNA technology and the knowledge of specific virulence factors of the pathogens have further facilitated the use of gene-deleted pathogens as vaccines. In gene-deleted pathogens, the pathogenicity and virulence are decreased without affecting immunogenicity. Gene-deleted agents cannot cause disease; however, immunogenic features are the same as in wild-type. Such agents must be genetically stable, easily reproducible, and easy to manipulate organisms. Vaccine strains of bacterial pathogens have been created that provide better protection than inactivated or killed vaccines. Gene-deleted vaccine technology is also used in marker vaccines that are used to differentiate between infected animals from vaccinated animals. Gene-deleted Salmonella enterica serovar typhimurium and serovar enteritidis have been licensed for use in poultry (Babu et al. [@CR3]; Meeusen et al. [@CR43]).

In pigs, pseudorabies virus marker vaccine generated a double gene (gE and TK) deleted virus (Ferrari et al. [@CR25]; Meeusen et al. [@CR43]). Also in cattle, BHV-1 virus marker vaccine produced gE deleted (Meeusen et al. [@CR43]; van Oirschot et al. [@CR76]). Another gene-deleted vaacine is against to Streptococcus equi. In horses, Streptococcus equi vaccine generated aroA gene deleted has been licensed (Jakobs et al. [@CR33]; Meeusen et al. [@CR43]).

Widjojoatmodjo et al. ([@CR78]) showed the possibility of generating deletion mutant viruses lacking the entire E2 or E^rns^ for CSFV. These mutants have the ability to develop in competent cell lines. So, they are safe vaccines. The mutant viruses stimulated powerful immuno response. The immune response comprise without generating new viral progeny (Widjojoatmodjo et al. [@CR78]). Related strategies have been used to build up several chimaeras by exchanging the E2 or the E^rns^ proteins from the attenuated C strain of CSFV with those from antigenically related pestiviruses (Van Gennip et al. [@CR73]).

The use of conventional vaccines against infectious bovine rhinotracheitis (IBR) does not seem to have consequenced in decrease of the prevalence of the disease. BHV1 marker vaccines comprise mutant in deletion of glycoproteins included genes which is nonessential. These marker vaccines can be used as diagnostic tests to separate cattle infected or vaccinated with marker vaccine (van Oirschot et al. [@CR76]). One of them is the Bovilis IBR Marker for cattle distributed by Intervet.

Virus-like Particles {#Sec3}
====================

Virus-like particles (VLPs) involve one or more recombinant proteins. They have supramolecular structures. These particles are 20--100 nm in size. They have icosahedral or rod-like structure (Jennings and Bachmann [@CR34]). VLPs are vaccine antigens and increase immunogenicity of the vaccine via their particulate structure. This offers an advantage for VPLs (Brun et al. [@CR10]). VLPs can be used as a vaccine or as a carrier for genetically modified antigens and have been studied for more than two decades. Hepatitis B virus (Zuckerman [@CR83]) and human papillomavirus (Stanley [@CR64]) vaccines are commercially presented. Studies are underway to develop vaccines against bluetongue virus, Rotavirus, and Parvovirus for veterinary application. VLPs have many advantages as a vaccine. They have high safety profile feature. Also, they have similarity to bacterial and viral structures and capability for large-scale production. The other advantage is the possibility of combining with other vaccine adjuvants.

VLPs induce strong and rapid antibody response. Induction of T-independent IgM responses activated by B cell activation via B cell receptor activation via vaccine antigens cross links (Bachmann and Zinkernagel [@CR4]; Brun et al. [@CR10]; Thyagarajan et al. [@CR66]).

VLPs are also processed as if they are exogenous antigens and presented by MHC class II molecules for helper T cell activation (Pejawar-Gaddy et al. [@CR47]; Win et al. [@CR79]).

Thus, the complement system activates and results in elevated phagocytosis. Strong immune response is further enhanced by the uptake of the particulate structure of VLPs by APC.

It was demonstrated that particulated antigens are much efficient than soluble antigens in inducing immune response (Lenz et al. [@CR40]).

CpG ODN and single-stranded RNA can be successfully combined with VLPs as a molecular adjuvant. Dendritic cells Stimulated by certain VLPs directly, for example, papillomavirus VLPs.

Bovine rotavirus virus has VLPs and they are highly immunogenic and has elicited protection against infections (Redmond et al. [@CR54]).

Other examples of vaccinations with VLPs include hepatitis B surface antigen VLPs (HBsAg-VLP), HIV 1, DV (dengue virus), Norovirus, and influenza A VLPs.

Many animal virus VLPs have been derived as an immunogenic. Examples for these VLPs include NDV, Porcine parvovirus (PPV), Rift Valley fever virus (RVFV) VLPs, Porcine circovirus VLPs, AIV, and bluetongue virus (BTV) VLPs (Jeoung et al. [@CR35]; Lynch et al. [@CR42]).

Many of these VLPs induce neutralizing antibodies and are protective in animal models.

Roy ([@CR56]) showed the immune protective effects of high immunogenic VLPs produced against bluetongue virus in sheep (Roy [@CR56]). Stewart et al. ([@CR65]) demonstrated that bluetongue virus VLPs were to be safe, highly effective, immunogens in sheep, reducing post-challenge viraemia to level below the threshold molecular detection limits (Stewart et al. [@CR65]).

VLPs vaccines currently are not available in veterinary field. It is anticipated that VLP vaccines are to be developed for use in this field in the near future.

Subunit Vaccines {#Sec4}
================

Two technologies used in vaccine production offer useful antigenic structures for the induction of satisfactory immune response. These include live-attenuated and inactivated or subunit vaccines. Live-attenuated vaccines are effective; however, they always possess some risks. The major advantage of inactivated and subunit vaccines are that they are safe to use (Day and Schultz [@CR17]). Despite this advantage, limited efficacy and limited immunization limit the use of such vaccines. DNA vaccines offer a new and strong approach over subunit vaccines (den Hurk et al. [@CR19]).

Subunit vaccines consist of semi-pure or purified proteins. Subunit vaccines have been produced by recombinant DNA technology since the 1990s and commercially available since the 1980s (Cohen [@CR14]; Rhodes et al. [@CR55]; Ulmer et al. [@CR68], [@CR67]). Since the first bacterial genome was sequenced in 1995, genome sequences were obtained for a number of bacterial, viral, and parasite genomes. However, the development of the bioinformatics resources and tools required to analyze these genomes allowed identification of surface exposed antigens, specific B, and T cell epitopes.

Subunit antigen productions can be obtained by both biochemical and DNA technologies. Biochemical techniques used in the production of subunit vaccines are useful where recombinant expression is not appropriate. This can be shown in fimbria of the bacteria. *Campylobacter jejuni* glycosylates many surface proteins and, therefore, they are best produced in *C. jejuni* rather than heterologous expression systems. This also applies for *Escherichia coli* that shows similar features (Wacker et al. [@CR77]).

*Escherichia coli* K99 vaccine for calf scours could be one of the best examples of subunit vaccines (Acres et al. [@CR1]).

Another example is the baculovirus used vaccine to porcine circovirus type 2 (Fachinger et al. [@CR23]).

Subunit vaccines offer some advantages. First, they stimulate strong humoral and cell-mediated immune response. They are considerably safe. They can be combined with other subunit vaccines.

In some occasions, subunit vaccines require adjuvants to induce a better immune response. Some glycoprotein production is costly with subunit vaccines. Subunit vaccines compatible with DIVA strategies. In bovine herpes virus, glycoprotein gD has been successfully used in subunit vaccine. Although immunization with gD has proven to be partially effective, it has not reduced the prevalence of the virus in the field, thus limiting its use (Harland et al. [@CR31]; van Drunen Littel-van den Hurk et al. [@CR71]).

Another research for Bovine Herpes virus 1 vaccination showed the subunit gD- and tgD-vaccinated calves shed significantly lower amounts of virus than the placebo or killed virus-immunized groups throughout the follow-up period. In the gD and tgD subunit vaccine vaccinated groups only one out of eight animals shed virus (van Drunen Littel-van den Hurk et al. [@CR71]).

A licensed porcine circovirus 2 vaccine is reported as a characteristic in inactivated baculovirus expressed PCV2 ORF2 protein in pigs by Intervet as a brand name Porcilis-PCV2 (Blanchard et al. [@CR7]). Another licensed porcine circovirus 2 vaccine is Suvaxyn PCV2 by Fort Dodge using the Inactivated PCV1-2 chimera (Fenaux et al. [@CR24]). Licensed vaccine against Pseudorabies virus for pigs is Suvaxyn Aujeszky distributed by Fort Dodge. The characteristic of vaccine is being a IgE- and thymidine kinase-deleted marker vaccine (Ferrari et al. [@CR25]). CSFV infection continues to be a subject in the studies exploring successful and effective vaccines. Vaccines are commercially available. The first one is Intervet and the other is Bayer. Baculovirus recombinant E2 protein has been used in the vaccines of both companies (van Aarle [@CR70]).

Many subunit vaccines have been tested all of which are not commercially available. These include vaccines against respiratory and enteric viruses, BVDV, BRSV, PI3, rotavirus, and coronavirus. Success of bacterial subunit vaccines over viral subunit vaccines results from recombinant and conventional production costs.

Recombinant vaccines prepared against respiratory system pathogens are commercially available. These include vaccines against *Mannheimia haemolytica* and *Actinobacillus pleuropneumoniae*. These vaccines have been formulated from leucotoxins and transferrin-binding proteins of these bacteria. Vaccine prepared for atrophic rhinitis has been formulated with nontoxic *Pasteurella multocida* dermonecrotic toxin. This toxin has been produced together with genetically modified *E. coli* strain and conventional *B. bronchiseptica* bacterin (Shewen and Wilkie [@CR62]).

Live-attenuated vaccines for classical swine flu (CSF) have a rapid onset of immunity and are effective at preventing transmission of infection (Van Oirschot [@CR75]). The only disadvantage is that vaccinated pigs cannot be differentiated from infected pigs. Vaccine studies following DIVA are ongoing for classical swine flu (CSF).

DIVA Vaccines (Marker Vaccines) {#Sec5}
===============================

Vaccines have been developed for many viral diseases occurring in farm animals. However, these vaccines interfere with the surveillance of the disease in serological tests and the individual country may lose its "free from infection" status. The most prominent example is the FMD that occurs in cattle. Many vaccines are available for use against FMD. These vaccines are used in disease control (Doel [@CR20]); however, they are not used in FMD free countries.

Marker vaccines have been developed for use in diagnostic tests by deleting a certain gene of pathogen (DIVA-differentiating infected from vaccinated animals). Antibody is not produced against the deleted gene of the pathogen. Therefore, it is possible to differentiate vaccinated from infected animals (van Oirschot [@CR74]). Many DIVA vaccines and diagnostic test kits for these vaccines have been developed. DIVA vaccines are used and developed against many diseases important for farm animals such as IBR, pseudorabies, classical swine fever (CSF), and FMD.

Originally this term was applied to gene-deleted marker vaccines for large DNA viruses when used with their vaccine specific serological tests, but it can also apply to subunit vaccines, heterologous vaccines, or some killed whole pathogen vaccines such as the highly purified FMD vaccine, which is used in conjunction with nonstructural protein-based serological tests (Ahrens et al. [@CR2]; Capua et al. [@CR12]; de Smit et al. [@CR18]; Sorensen et al. [@CR63]).

Numerous strategies have been used to develop DIVA vaccines against CSFV, with variable achievement regarding their capacity to reduce viral replication in animals or to avoid transplacental transmission of the virus. These vaccines include full-length CSFV E2 glycoprotein or fractions, mainly (Hammond et al. [@CR30], [@CR29]).

Glycoprotein E (gE)-deleted DIVA vaccine for IBR has been developed with European conventional methodology (van Oirschot et al. [@CR76]). gE protein gene is not required for viral replication of IBR. However, this gene plays an important role to spread across the host cells. ELISA technique and PCR amplification have been developed for diagnostic tests of gE-deleted DIVA vaccine (Perrin et al. [@CR49]; Schynts et al. [@CR59]). DIVA strategy developed by deletion of gE gene is also used for Aujeszky's disease (Pensaert et al. [@CR48]).

DIVA vaccine developed for classical swine flu (CSF) has been produced in viral envelope glycoprotein E2 protein baculovirus/insect cell system and formulated with adjuvant. ELISA diagnostic kit has also been produced for this DIVA vaccine (Moormann et al. [@CR44]; van Aarle [@CR70]). As usual, DIVA vaccines have some disadvantages compared to conventional live or attenuated vaccines (Beer et al. [@CR6]).

The host body must be exposed to more than one epitope of the pathogen in order to induce a strong immune response. With this purpose, studies have focused to develop vaccines combining capsid proteins (Grubman [@CR28]).

In many diseases, DIVA vaccine is needed for surveillance or epidemiological data. These particularly include peste des petits ruminants virus, bluetongue virus in cattle, NDV and AIV in poultry, and bovine viral diarrhea virus.
